These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 2737730

  • 1. Central vasopressin raises arterial pressure by sympathetic activation and vasopressin release.
    Janiak P, Kasson BG, Brody MJ.
    Hypertension; 1989 Jun; 13(6 Pt 2):935-40. PubMed ID: 2737730
    [Abstract] [Full Text] [Related]

  • 2. Vasopressin: mechanism of central cardiovascular action in conscious rats.
    Rohmeiss P, Becker H, Dietrich R, Luft F, Unger T.
    J Cardiovasc Pharmacol; 1986 Jun; 8(4):689-96. PubMed ID: 2427805
    [Abstract] [Full Text] [Related]

  • 3. Differential actions of neuronal and hormonal vasopressin on blood pressure and baroreceptor reflex sensitivity in rats.
    Unger T, Rohmeiss P, Demmert G, Luft FC, Ganten D, Lang RE.
    J Cardiovasc Pharmacol; 1986 Jun; 8 Suppl 7():S81-6. PubMed ID: 2434779
    [Abstract] [Full Text] [Related]

  • 4. Central and peripheral injections of the 5-HT2 agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, modify cardiovascular function through different mechanisms.
    Dedeoğlu A, Fisher LA.
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1027-34. PubMed ID: 1762059
    [Abstract] [Full Text] [Related]

  • 5. Central and peripheral vasopressin interact differently with sympathetic nervous system and renin-angiotensin system in renal hypertensive rabbits.
    Kumagai H, Suzuki H, Ichikawa M, Matsumura Y, Jimbo M, Ryuzaki M, Saruta T.
    Circ Res; 1993 Jun; 72(6):1255-65. PubMed ID: 8495554
    [Abstract] [Full Text] [Related]

  • 6. GABA agonists inhibit central sodium-induced vasopressin-dependent increases in arterial pressure.
    Brennan TJ, Morris M, Haywood JR.
    Eur J Pharmacol; 1984 Aug 17; 103(3-4):223-34. PubMed ID: 6489442
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms underlying the cardiovascular responses to intrathecal vasopressin administration in rats.
    Riphagen CL, Pittman QJ.
    Can J Physiol Pharmacol; 1989 Apr 17; 67(4):269-75. PubMed ID: 2758369
    [Abstract] [Full Text] [Related]

  • 8. Central effects of somatostatin: pressor response, AVP release, and sympathoinhibition.
    Rettig R, Geist R, Sauer U, Rohmeiss P, Unger T.
    Am J Physiol; 1989 Sep 17; 257(3 Pt 2):R588-94. PubMed ID: 2571303
    [Abstract] [Full Text] [Related]

  • 9. Pressor responses in rats following intravenous dynorphin A(1-13) administration are blocked by AVP-V1 receptor antagonism.
    Thornhill J, Gregor L, Pittman Q.
    Regul Pept; 1990 Oct 29; 31(1):1-10. PubMed ID: 1980152
    [Abstract] [Full Text] [Related]

  • 10. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin.
    Hinojosa C, Haywood JR.
    J Pharmacol Exp Ther; 1986 Aug 29; 238(2):492-6. PubMed ID: 2874211
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of centrally administered ET-1-induced increases in systemic arterial pressure and AVP secretion.
    Rossi NF, O'Leary DS, Chen H.
    Am J Physiol; 1997 Jan 29; 272(1 Pt 1):E126-32. PubMed ID: 9038861
    [Abstract] [Full Text] [Related]

  • 12. Interrelationship between central bradykinin and vasopressin in conscious rats.
    Brooks DP, Share L, Crofton JT, Nasjletti A.
    Brain Res; 1986 Apr 16; 371(1):42-8. PubMed ID: 3754782
    [Abstract] [Full Text] [Related]

  • 13. Central effects of prostaglandin E2 on blood pressure and plasma renin activity in rats. Role of the sympathoadrenal system and vasopressin.
    Okuno T, Lindheimer MD, Oparil S.
    Hypertension; 1982 Apr 16; 4(6):809-16. PubMed ID: 6292084
    [Abstract] [Full Text] [Related]

  • 14. Pressor and renal vasoconstrictor effects of NG-nitro-L-arginine as affected by blockade of pressor mechanisms mediated by the sympathetic nervous system, angiotensin, prostanoids and vasopressin.
    Pucci ML, Lin L, Nasjletti A.
    J Pharmacol Exp Ther; 1992 Apr 16; 261(1):240-5. PubMed ID: 1560371
    [Abstract] [Full Text] [Related]

  • 15. Central and systemic effects of a vasopressin V1 antagonist on MAP recovery after haemorrhage in rats.
    Johnson JV, Bennett GW, Hatton R.
    J Cardiovasc Pharmacol; 1988 Oct 16; 12(4):405-12. PubMed ID: 2465440
    [Abstract] [Full Text] [Related]

  • 16. GABA agonists inhibit the vasopressin-dependent pressor effects of central angiotensin II.
    Brennan TJ, Morris M, Haywood JR.
    Neuroendocrinology; 1984 Nov 16; 39(5):429-36. PubMed ID: 6514131
    [Abstract] [Full Text] [Related]

  • 17. Interaction of opioids and vasopressin in central action of angiotensin II in conscious rabbits.
    Fukuhara M, Matsumura K, Abe I, Fujishima M.
    Hypertens Res; 1998 Jun 16; 21(2):89-95. PubMed ID: 9661804
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of AVP in pressor responses during activation of central TxA2/PGH2 receptors.
    Wilcox CS, Gao H, Verbalis JG, Welch WJ.
    Am J Physiol; 1997 Oct 16; 273(4):H1927-32. PubMed ID: 9362262
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.